Display Settings:

Format

Send to:

Choose Destination
    Lung Cancer. 2011 Dec;74(3):355-63. Epub 2011 Aug 31.

    Predictive markers in the adjuvant therapy of non-small cell lung cancer.

    Source

    Department of Medicine I, Medical University of Vienna, Vienna, Austria. martin.filipits@meduniwien.ac.at

    Abstract

    Adjuvant chemotherapy increases the 5-year survival rate of patients with completely resected non-small cell lung cancer (NSCLC) by absolute 5%. Molecular-targeted therapies and predictive biomarkers to select those patients who benefit hold promise to further improve the outcome. Several biomarkers including ERCC1, BRCA1, EGFR, or gene signatures have been characterized in retrospective analyses of adjuvant therapy trials. However, differences in trial design and laboratory tests might have affected the outcome and might explain discordant results. With regard to many biomarkers, laboratory tests for their assessment remain to be standardized. After standardization of these tests and further validation studies, biomarkers might allow individualizing adjuvant treatment in patients with completely resected NSCLC in the future.

    Copyright © 2011. Published by Elsevier Ireland Ltd.

    PMID:
    21885151
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk